Dabigatran Etexilate: Clinical Implications in Dermatologic SurgeryBOTA, James P; LEBLANC, Keith G; SHEEHAN, Daniel J et al.Dermatologic surgery. 2012, Vol 38, Num 4, pp 675-676, issn 1076-0512, 2 p.Article

Development and Validation of a Stability-Indicating Liquid Chromatography Method for the Determination of Dabigatran Etexilate in CapsulesBERNARDI, Raquel M; FRÖEHLICH, Pedro E; BERGOLD, Ana M et al.Journal of AOAC International. 2013, Vol 96, Num 1, pp 37-41, issn 1060-3271, 5 p.Article

Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activityVAN RYN, Joanne; STANGIER, Joachim; HAERTTER, Sebastian et al.Thrombosis and haemostasis. 2010, Vol 103, Num 6, pp 1116-1127, issn 0340-6245, 12 p.Article

Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatranSTANGIER, Joachim; FEURING, Martin.Blood coagulation & fibrinolysis. 2012, Vol 23, Num 2, pp 138-143, issn 0957-5235, 6 p.Article

Dabigatran etexilateDUBOIS, Eline A; COHEN, Adam F.British journal of clinical pharmacology. 2010, Vol 70, Num 1, pp 14-15, issn 0306-5251, 2 p.Article

Dabigatran: how the drug company withheld important analysesCOHEN, Deborah.BMJ (Overseas and retired doctors ed.). 2014, Vol 349, Num 7968, pp 15-20, issn 1759-2151, 6 p.Article

Dabigatran, a Direct Thrombin Inhibitor, Demonstrates Antifibrotic Effects on Lung FibroblastsBOGATKEVICH, Galina S; LUDWICKA-BRADLEY, Anna; SILVER, Richard M et al.Arthritis and rheumatism. 2009, Vol 60, Num 11, pp 3455-3464, issn 0004-3591, 10 p.Article

Evaluation of Dabigatran Exposures Reported to Poison Control CentersCONWAY, Susan E; SCHAEFFER, Scott E; HARRISON, Donald L et al.The Annals of pharmacotherapy. 2014, Vol 48, Num 3, pp 354-360, issn 1060-0280, 7 p.Article

Removal of Dabigatran by HemodialysisCHANG, Don N; DAGER, William E; CHIN, Andrew I et al.American journal of kidney diseases. 2013, Vol 61, Num 3, pp 487-489, issn 0272-6386, 3 p.Article

Dabigatran EtexilateSANFORD, Mark; PLOSKER, Greg L.Drugs (Basel). 2008, Vol 68, Num 12, pp 1699-1709, issn 0012-6667, 11 p.Article

Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time AssayGOSSELIN, Robert C; DWYRE, Denis M; DAGER, William E et al.The Annals of pharmacotherapy. 2013, Vol 47, Num 12, pp 1635-1640, issn 1060-0280, 6 p.Article

Activated prothrombin complex concentrate for dabigatran-associated bleedingSCHULMAN, Sam; RITCHIE, Bruce; GOY, Jennifer K et al.British journal of haematology. 2014, Vol 164, Num 2, pp 308-310, issn 0007-1048, 3 p.Article

Overview of Direct Thrombin Inhibitors in Clinical PracticeBOUNAMEAUX, Henri.Seminars in thrombosis and hemostasis. 2008, Vol 34, pp 12-17, issn 0094-6176, 6 p., SUP1Article

Evaluation of Dabigatran Utilization and Risk Among Hospitalized PatientsSIDMAN, Eric; PROBST, Luke A; DARKO, William et al.The Annals of pharmacotherapy. 2014, Vol 48, Num 3, pp 349-353, issn 1060-0280, 5 p.Article

Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxabanHERRMANN, Richard; THOM, James; WOOD, Alicia et al.Thrombosis and haemostasis. 2014, Vol 111, Num 5, pp 989-995, issn 0340-6245, 7 p.Article

A NEW ERA OF ANTICOAGULATIONHAINAUT, P. H.Acta clinica belgica (English ed.). 2012, Vol 67, Num 6, pp 394-398, issn 1784-3286, 5 p.Article

Nouveaux anticoagulants: ont-ils déjà une place en oncologie ? : Thrombose et cancer = Novel anticoagulants: do they already have a place in oncology departments ? : Thrombosis and cancerDICATO, M; PLAWNY, L.Oncologie (Paris). 2012, Vol 14, Num 12, pp 659-662, issn 1292-3818, 4 p.Article

Plasma-Diluted Thrombin Time to Measure Dabigatran Concentrations During Dabigatran Etexilate TherapyAVECILLA, Scott T; FERRELL, Chris; CHANDLER, Wayne L et al.American journal of clinical pathology. 2012, Vol 137, Num 4, pp 572-574, issn 0002-9173, 3 p.Article

Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assaysLINDAHL, Tomas L; BAGHAEI, Fariba; BLIXTER, Inger Fagerberg et al.Thrombosis and haemostasis. 2011, Vol 105, Num 2, pp 371-378, issn 0340-6245, 8 p.Article

New anticoagulants: how to deal with treatment failure and bleeding complicationsKAZMI, Rashid S; LWALEED, Bashir A.British journal of clinical pharmacology. 2011, Vol 72, Num 4, pp 593-603, issn 0306-5251, 11 p.Article

Dabigatran (Pradaxa^®): efficacité et tolérance = Dabigatran (Pradaxa^®): efficacy and safetyROSENCHER, N; BELLAMY, L.Annales françaises d'anesthésie et de réanimation. 2009, Vol 28, Num SEPT, issn 0750-7658, S15-S22, SUP1Article

Evaluation of Pharmacist-Managed Dabigatran in an Inpatient SettingTEDDERS, Kristen M; LUCEY, Michael F; EDWIN, Stephanie B et al.The Annals of pharmacotherapy. 2013, Vol 47, Num 12, pp 1649-1653, issn 1060-0280, 5 p.Article

Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatranSTIEF, Thomas W.Blood coagulation & fibrinolysis. 2012, Vol 23, Num 7, pp 619-621, issn 0957-5235, 3 p.Article

Place des nouveaux anticoagulants oraux en salle de cardiologie interventionnelle = Role of new anticoagulants in interventional cardiologyBRASSELET, C; DUVAL, S.Annales de cardiologie et d'angéiologie (Paris). 2012, Vol 61, Num 6, pp 453-456, issn 0003-3928, 4 p.Article

Hemodialysis for the Treatment of Pulmonary Hemorrhage From Dabigatran OverdoseCHEN, Betty C; SHETH, Nijal R; DADZIE, Kobena A et al.American journal of kidney diseases. 2013, Vol 62, Num 3, pp 591-594, issn 0272-6386, 4 p.Article